

FIG. 1A and FIG. 1B

Hybrid ImmunoCapture (HIC) Assay




Fig. 1A




Fig. 1B

FIG. 2: Plasma Lp-PLA2 Activity in HIC-ThioPAF Assay (2c10 as capturing mAb)




FIG. 3: Plasma Lp-PLA2 Activity in HIC-ThioPAF Assay (B200.1 as capturing mAb)




FIG. 4: Plasma Lp-PLA2 Activity in HIC-ThioPAF Assay (B501.1 as capturing mAb)





FIG. 5: Plasma Lp-PLA2 Activity in HIC-MNP Assay (2c10 as capturing mAb)



○ = with 1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidylcholine substrate (MNP)
□ = without 1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidylcholine substrate

FIG. 6: Plasma Lp-PLA2 Activity In Commercial ThioPAF Assay





FIG. 7: Plasma sample background in Improved ThioPAF Assay, with DTNB but w/o substrate added



○ = without 2-thio PAF substrate; with DTNB added

FIG. 8: Plasma Lp-PLA2 Activity in Improved ThioPAF Assay

